Knight Therapeutics Inc T.GUD

Alternate Symbol(s): KHTRF

Healthcare

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.

TSX:GUD - Post by User

Knight Therapeutics Inc > Q3 Results

<< Previous

Bullboard Posts

Next >>

Comment by EbbFlow88on Nov 11, 2021 5:15pm

129 Views

Post# 34117074

RE:Q3 Results

Well said. I would have grabbed more as well if I had some excess cash.

The cash from operations is my main focus as they can redeploy that. Another 1M shares have been repurchased and I'm sure future deals currently in the pipeline.

The market can only ignore this for so long. I would think this will break out of this long base sooner than later. I'm still shocked the shares can be grabbed for this price.

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario